Yasmeen A - Search Results

1

Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.

Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, Gotlieb WH. Laskov I, et al. Among authors: yasmeen a. Gynecol Oncol. 2014 Sep;134(3):607-14. doi: 10.1016/j.ygyno.2014.06.014. Epub 2014 Jun 24. Gynecol Oncol. 2014. PMID: 24972190 Clinical Trial.

2

BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.

Beauchamp MC, Knafo A, Yasmeen A, Carboni JM, Gottardis MM, Pollak MN, Gotlieb WH. Beauchamp MC, et al. Among authors: yasmeen a. Gynecol Oncol. 2009 Nov;115(2):193-8. doi: 10.1016/j.ygyno.2009.07.009. Epub 2009 Aug 21. Gynecol Oncol. 2009. PMID: 19699512

3

Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer.

Beauchamp MC, Yasmeen A, Knafo A, Gotlieb WH. Beauchamp MC, et al. Among authors: yasmeen a. J Oncol. 2010;2010:257058. doi: 10.1155/2010/257058. Epub 2010 Jan 5. J Oncol. 2010. PMID: 20069126 Free PMC article.

4

Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins.

Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Gotlieb WH. Yasmeen A, et al. Gynecol Oncol. 2011 Jun 1;121(3):492-8. doi: 10.1016/j.ygyno.2011.02.021. Epub 2011 Mar 8. Gynecol Oncol. 2011. PMID: 21388661

5

Relevance of the OCT1 transporter to the antineoplastic effect of biguanides.

Segal ED, Yasmeen A, Beauchamp MC, Rosenblatt J, Pollak M, Gotlieb WH. Segal ED, et al. Among authors: yasmeen a. Biochem Biophys Res Commun. 2011 Nov 4;414(4):694-9. doi: 10.1016/j.bbrc.2011.09.134. Epub 2011 Oct 2. Biochem Biophys Res Commun. 2011. PMID: 21986525

6

Combination of serum biomarkers to differentiate malignant from benign ovarian tumours.

He G, Holcroft CA, Beauchamp MC, Yasmeen A, Ferenczy A, Kendall-Dupont J, Mes-Masson AM, Provencher D, Gotlieb WH. He G, et al. Among authors: yasmeen a. J Obstet Gynaecol Can. 2012 Jun;34(6):567-574. doi: 10.1016/S1701-2163(16)35273-2. J Obstet Gynaecol Can. 2012. PMID: 22673173

7

Akt-activated endothelium constitutes the niche for residual disease and resistance to bevacizumab in ovarian cancer.

Guerrouahen BS, Pasquier J, Kaoud NA, Maleki M, Beauchamp MC, Yasmeen A, Ghiabi P, Lis R, Vidal F, Saleh A, Gotlieb WH, Rafii S, Rafii A. Guerrouahen BS, et al. Among authors: yasmeen a. Mol Cancer Ther. 2014 Dec;13(12):3123-36. doi: 10.1158/1535-7163.MCT-13-1053. Epub 2014 Oct 15. Mol Cancer Ther. 2014. PMID: 25319392

8

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.

Amin O, Beauchamp MC, Nader PA, Laskov I, Iqbal S, Philip CA, Yasmeen A, Gotlieb WH. Amin O, et al. Among authors: yasmeen a. BMC Cancer. 2015 Oct 29;15:817. doi: 10.1186/s12885-015-1803-y. BMC Cancer. 2015. PMID: 26510816 Free PMC article.

9

Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines.

Laskov I, Abou-Nader P, Amin O, Philip CA, Beauchamp MC, Yasmeen A, Gotlieb WH. Laskov I, et al. Among authors: yasmeen a. Int J Gynecol Cancer. 2016 Sep;26(7):1213-21. doi: 10.1097/IGC.0000000000000761. Int J Gynecol Cancer. 2016. PMID: 27643646

10

Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer.

Kessous R, Laskov I, Abitbol J, Bitharas J, Yasmeen A, Salvador S, Lau S, Gotlieb WH. Kessous R, et al. Among authors: yasmeen a. Gynecol Oncol. 2017 Mar;144(3):474-479. doi: 10.1016/j.ygyno.2016.12.017. Epub 2016 Dec 29. Gynecol Oncol. 2017. PMID: 28041690

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

198 results

Search Page

Filters